Sarah Cannon to Present Latest Cancer Research Insights at 2019 American Society of Clinical Oncology’s Annual Meeting
May 30, 2019NASHVILLE, Tenn.–(BUSINESS WIRE)–Today, Sarah
Cannon announced that it will present its latest cancer research
insights through more than 100 abstracts and presentations at the American
Society of Clinical Oncology’s (ASCO®) Annual Meeting hosted in
Chicago, from May 31-June 4, 2019. The ASCO® Annual Meeting brings
together more than 40,000 cancer experts from around the world to review
the latest research and discuss this year’s theme of “Caring for Every
Patient, Learning from Every Patient.” Sarah Cannon experts will
participate in a number of presentations and educational sessions
focused on immunotherapies, including cellular therapy, and targeted
investigational agents that are transforming the delivery of cancer care
for patients.
“The research presented at this year’s Annual Meeting will highlight
Sarah Cannon’s involvement in the latest CAR T-Cell Therapy approaches,
bispecific antibodies, novel targeted therapies as well as personalized
cancer vaccines. We continue to be excited about the developments being
made in individualized cancer therapies and the potential impact for
patients worldwide,” said Howard
A. “Skip” Burris, III, MD, President of Clinical Operations and
Chief Medical Officer at Sarah Cannon. Dr. Burris will serve as the
ASCO® President for the 2019-2020 term, and will be inducted into his
position on Monday, June 3, during the Annual Meeting.
A number of Sarah Cannon’s presentations will focus on insights from
more than 50 phase 1 studies, which include novel immunotherapy
combinations and CAR T-Cell, as well as mutation-targeted agents.
An oral presentation titled “Safety and Preliminary Antitumor
Activity of U3-1402: A HER3-Targeted Antibody Drug Conjugate in EGFR
TKI-Resistant, EGFRm NSCLC,” will feature the work of Melissa
Johnson, MD, an investigator on the trial. Additionally, Sarah
Cannon’s work, under the leadership of Gerald
Falchook, MD, on the phase I trial investigating the targeted
therapy KRASG12C will be highlighted in an oral presentation at the
meeting. The phase 1 dose escalation study of the ERK inhibitor
LY3214996 will also be highlighted in an oral presentation, featuring
the work of Johanna
Bendell, MD, and Manish
Patel, MD.
Lowell
Hart, MD, will highlight the latest in novel biologics through an
oral presentation on the “Effect of Trilaciclib, a CDK 4/6 Inhibitor,
on Myelosuppression in Patients with Previously Treated Extensive-Stage
Small Cell Lung Cancer Receiving Topotecan.” Sarah Cannon’s work in
cellular therapy, under the leadership of William
Donnellan, MD, will be showcased in an oral presentation on the
phase I results of KTE-X19 in adult patients with relapsed/refractory
acute lymphoblastic leukemia.
Additionally, Sarah Cannon investigators are presenting noteworthy
studies as first authors through the following presentations:
-
Dr. Burris’ poster presentation on a personalized cancer vaccine
titled “A Phase I Multicenter Study to Assess the Safety,
Tolerability, and Immunogenicity of mRNA-4157 Alone in Patients with
Resected Solid Tumors and in Combination with Pembrolizumab in
Patients with Unresectable Solid Tumors” on June 1 from
1:15-2:45pm in Hall D1. -
A poster authored by Kathleen
Moore, MD, titled “Adavosertib with Chemotherapy in Patients
with Platinum-Resistant Ovarian Cancer: An Open Label, Four-Arm, Phase
II Study” featured in a poster discussion on June 1 from 4:30-6pm
in S406. -
A poster authored by Judy
Wang, MD, titled “First-in-Human Study of AZD5153, a
Small Molecule Inhibitor of Bromodomain Protein 4, in Patients with
Relapsed/Refractory Malignant Solid Tumor and Lymphoma: Preliminary
Data” on June 1 from 8-11am in Hall A. -
Dr. Johnson’s poster on “A Phase I, Open Label, Multicenter
Dose Escalation Study of AZD2811 Nanoparticle in Patients with
Advanced Solid Tumors,” presented on June 1 from 8-11am in Hall A. -
Dr. Patel’s poster titled “Open-Label, Multicenter, Phase I Study
to Assess Safety and Tolerability of Adavosertib plus Durvalumab in
Patients with Advanced Solid Tumors,” showcased on June 1 from
8-11am in Hall A. -
A poster authored by Dr. Bendell on a “Phase 1, Open-Label,
Dose-Escalation Study of M3814 + Avelumab ± Radiotherapy in Patients
with Advanced Solid Tumors” displayed on June 1 from 8-11am in
Hall A. -
A poster authored by Erika
Hamilton, MD, discussing metastatic breast cancer therapies titled
“Next-Generation Sequencing Results Among Hormone
Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative
Metastatic Breast Cancer Patients Treated with a CDK4 & 6 Inhibitor: A
Retrospective Observational Study Based on Real-World Data” on
June 2 from 8-11am in Hall A. Dr. Hamilton will also present data from
“Phase I Dose Escalation of H3B-6545, a First-In-Class Highly
Selective Erα Covalent Antagonist, in Women with ER-Positive,
HER2-Negative Breast Cancer,” in another poster the same day. -
Two posters authored by Ian
Flinn, MD, titled “Effect of Dose Modifications on Response to
Duvelisib in Patients with Relapsed/Refractory CLL/SLL in the DUO Trial”
and “ZUMA-8: A Phase 1/2 Multicenter Study Evaluating KTE-X19 In
Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia”
both presented on June 2 from 8-11am in Hall A. -
A poster authored by Dax
Kurbegov, MD, discussing “Qualifying Sites for Oncology
Clinical Trials” as a part of the Health Services Research,
Clinical Informatics, and Quality of Care session on June 1 from
1:15-4:45pm in Hall A.
Sarah Cannon experts will also share insights through education sessions
and oral presentations including:
-
Carlos
Bachier, MD, will discuss “Barriers to CAR T-Cell Treatment in
the Community” during an education session on CAR T-Cell Therapy
on May 31 from 5:10-5:30pm in E451. -
Dr. Johnson will discuss “Case 3: Managing Immunotherapy in
Patients with Renal Insufficiency (PD-L1 Low)” during the
Challenges in Use of Immunotherapy in Non-Small Cell Lung Cancer:
Where the Rubber Meets the Road education session on May 31 at 4:30pm
in Hall D1. Dr. Johnson will also serve as the session chair for the
clinical science symposium on “Fine-Tuning Checkpoint Inhibition:
Biomarkers of Response and Resistance” on June 1 at 8am in Hall
D1, and as the chair during the Highlights of the Day session on June
2 at 7:30am in Hall D1. -
Dr. Hamilton will present on “The Metastatic Breast Cancer Project:
Engaging Patients, Advancing Research” in an education session on
Tweets, Chats, and Posts: Using Social Media to Transcend Boundaries
and Create Opportunities for Patients on May 31 at 4:30pm in S404. She
will also serve as the chair of the Breast Cancer Metastatic Oral
Abstract session on June 4 at 9:45am in Hall D1. -
Mick
Correll, President of Genospace – Sarah Cannon’s precision
medicine company, will participate as a panelist in an education
session focused on the Biden Cancer Initiative titled “Biden Cancer
Initiative Colloquium: Clinical Trial Enrollment–Breaking the 5%
Barrier Once and For All” on June 1 at 1:15pm in E350. -
Faithlore
Gardner, MD, will serve as a chair during an oral abstract session
discussing “Health Services Research, Clinical Informatics, and
Quality of Care II” on June 2 at 8am in S404. -
Jesus
Berdeja, MD, will participate in an oral abstract discussion on
“It’s Not All About CAR T: What’s New in Immunotherapy?” on
June 2 at 9:45am in E451.
For a full listing of all presentations authored by Sarah Cannon
investigators, visit sarahcannon.com/asco.
The researchers represent Sarah Cannon’s global network of strategic
sites:
Colorado
Blood Cancer Institute, Sarah
Cannon Research Institute at Florida Cancer Specialists, Sarah
Cannon Research Institute at HCA Midwest Health (Kansas City), Sarah
Cannon Research Institute at HealthONE (Denver), Sarah
Cannon Research Institute at Tennessee Oncology, Sarah
Cannon Research Institute – United Kingdom, and The
Stephenson Cancer Center at the University of Oklahoma.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute is the research arm of HCA Healthcare’s
Cancer Institute, Sarah Cannon. Focused on advancing therapies for
patients, it is one of the world’s leading clinical research
organizations conducting community-based clinical trials throughout the
United States and United Kingdom. A leader in drug development, Sarah
Cannon has led more than 370 first-in-human clinical trials since its
inception in 1993, and has been a clinical trial leader in the majority
of approved cancer therapies over the last 10 years. Additionally, Sarah
Cannon offers management, regulatory, and other research support
services for drug development and industry sponsors as well as strategic
investigator sites through its contract research organization (CRO),
Sarah Cannon Development Innovations. For more information, visit sarahcannon.com.
Contacts
Samantha Maxwell
[email protected]